COLON ADENOCARCINOMA
Clinical trials for COLON ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new COLON ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for COLON ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New mRNA vaccine aims to stop colorectal cancer recurrence in High-Risk patients
Disease control OngoingThis study tests an experimental mRNA vaccine (RO7198457) in people with stage 2 or 3 colorectal cancer who had surgery but still have cancer DNA in their blood. The goal is to see if the vaccine can prevent the cancer from returning better than simply watching and waiting. About…
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
New combo therapy tested to prevent colon cancer return
Disease control OngoingThis study tested whether adding a targeted drug (bevacizumab) to standard chemotherapy helps prevent colon cancer from coming back in people with high-risk stage II colon cancer after surgery. About 2,400 participants were randomly assigned to receive either chemotherapy alone o…
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Immunotherapy combo shows promise in High-Risk colon cancer trial
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps prevent cancer from returning in people with stage III colon cancer that has a specific DNA repair problem (dMMR). About 712 participants received either chemotherapy alone or chemo…
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
New combo therapy shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingThis study tests a combination of two drugs, cabozantinib and nivolumab, in people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can stop or shrink the cancer for at least 16 weeks. About 48 adults with a spe…
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 29, 2026 14:19 UTC
-
New drug cocktail aims to stop BRAF colon cancer in its tracks
Disease control OngoingThis study tests whether adding two targeted drugs (encorafenib and cetuximab) after standard surgery and chemotherapy can lower the chance of cancer coming back in people with a specific genetic type of stage II/III colon cancer (BRAF V600E). Participants either receive the drug…
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 26, 2026 12:00 UTC
-
Scientists hunt for genetic clues to rising colorectal cancer in young adults
Knowledge-focused OngoingThis study looks at genetic markers that may increase the risk of developing colorectal cancer at a young age (18-50). Researchers will compare data from 818 patients and their family members to find patterns in genes, treatments, and outcomes. The goal is to better identify who …
Matched conditions: COLON ADENOCARCINOMA
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:48 UTC